Item 8.01 Other Events
As previously announced, on November 27, 2020 (the "Agreement Date"), Sage
Therapeutics, Inc. (the "Company") entered into a Collaboration and License
Agreement (the "Collaboration Agreement") with Biogen MA Inc. ("BIMA") and
Biogen International GmbH (together with BIMA, "Biogen") and into a stock
purchase agreement (the "Stock Purchase Agreement") with BIMA. In accordance
with its terms, the Collaboration Agreement became effective on December 28,
2020, the date that the parties received clearance for the proposed transactions
under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.
On December 31, 2020, the Company received an $875.0 million upfront fee from
Biogen pursuant to the Collaboration Agreement and issued and sold 6,241,473
shares of its common stock to BIMA pursuant to the Stock Purchase Agreement at a
price of approximately $104.14 per share, a premium of 40% over the
volume-weighted average share price for the 30 days ending on the day prior to
the Agreement Date, for an aggregate purchase price of $650.0 million.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses
SAGE THERAPEUTICS, INC. 
